<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Benzodiazepines for treatment of procedural anxiety in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Benzodiazepines for treatment of procedural anxiety in adults</h1>
<div class="graphic"><div class="figure"><div class="ttl">Benzodiazepines for treatment of procedural anxiety in adults</div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="25%"></colgroup> <tbody> <tr> <td class="subtitle1">Benzodiazepine</td> <td class="subtitle1">Oral dose*<sup>¶</sup></td> <td class="subtitle1">Initial parenteral dose*<sup>¶</sup></td> <td class="subtitle1">Onset (minutes)</td> </tr> <tr> <td>Alprazolam</td> <td>0.5 mg</td> <td>Not available</td> <td>Oral: 15 to 30 (delayed with high fat meal)</td> </tr> <tr> <td>Diazepam</td> <td>2 to 10 mg</td> <td>0.03 to 0.1 mg/kg intravenous (2 to 10 mg per dose)<sup>Δ</sup></td> <td> <p>Oral: 15</p> Intravenous: 2 to 5 </td> </tr> <tr> <td>Lorazepam</td> <td>1 to 2 mg</td> <td>0.02 to 0.04 mg/kg intravenous (1 to 4 mg per dose)</td> <td> <p>Oral: 15 to 30</p> Intravenous: ≤10 to 15</td> </tr> <tr> <td>Midazolam</td> <td>7.5 mg<sup>◊</sup><sup>[1,2]</sup> (intranasal dosing is provided in footnote<sup>§</sup>)</td> <td>0.01 to 0.02 mg/kg intravenous (0.5 to 2 mg per dose)</td> <td> <p>Oral: 10 to 20</p> <p>Intranasal: ≤5</p> Intravenous: 1 to 3</td> </tr> <tr> <td>Oxazepam</td> <td>15 to 30 mg</td> <td>Not available</td> <td>Oral: 60 to 120</td> </tr> <tr> <td>Temazepam</td> <td>15 to 30 mg</td> <td>Not available</td> <td>Oral: 30 to 60</td> </tr> </tbody></table></div><div class="graphic_lgnd"><ul>
<li>Some patients experience mild symptoms such as nausea, lightheadedness, fatigue, unsteadiness, or psychomotor impairment for up to 24 hours after the administration of sedative agents. This should be made clear to the patient and the patient should be warned not to drive until side effects have completely resolved. Refer to UpToDate topic review of procedural anxiety  in adults.</li>
<li>Equipment, medications, and personnel skilled in advanced cardiac life support and with knowledge of the effects of sedatives and reversal agents must be available for intravenous administration of benzodiazepines.</li>
<li>For approach to benzodiazepine selection, refer to topic text.</li>
</ul></div><div class="graphic_footnotes"><p>* <strong>Individualization of dose</strong>: In most adults, a standard (non-weight based) dose at the lower end to middle of dose range shown in table is appropriate. However, patients with regular benzodiazepine or alcohol use leading to tolerance may need a dose in the upper end of the range. Approximately 50% reduction of dose is needed for older (&gt;60 years) or debilitated adults, patients with low cardiac output, or those premedicated with opioid analgesics. If intravenous administration is used, a slow rate of administration (eg over 2 to 5 minutes or more) with frequent assessments of cardiorespiratory and sedative effects is recommended. In patients with obesity, standard, non-weight-based initial dosing is preferred. Standard adult doses are shown in parentheses following intravenous weight-based doses.</p>
<p>¶ Repeated dose(s) usually equal to one-half of initial dose may be needed 30 to 60 minutes after oral administration or 5 to 30 minutes after intravenous administration, based upon response and duration of procedure.</p>
<p>Δ Administer by slow intravenous push in a relatively large vein.</p>
<p>◊ In the United States, oral midazolam is available as a syrup approved for use in pediatric patients; use in adult patients is off-label. Oral tablets are available elsewhere in the world; refer to local product information for approved uses.</p>
    
    § Midazolam injection solution (5 mg/mL) may be administered intranasally at a dose of 1 to 4 mg<sup>[3]</sup>. The injection solution is irritating to nasal passages.</div><div class="graphic_reference">References:
    <ol>
<li>Mui LM, Teoh AY, Ng EK, et al. Premedication with orally administered midazolam in adults undergoing diagnostic upper endoscopy: a double-blind placebo-controlled randomized trial. Gastrointest Endosc 2005; 61:195.</li>
<li>Kuganeswaran E, Clarkston WK, Cuddy PG, et al. A double-blind placebo controlled trial of oral midazolam as premedication before flexible sigmoidoscopy. Am J Gastroenterol 1999; 94:3215.</li>
<li>Hollenhorst J, Munte S, Friedrich L, et al. Using intranasal midazolam spray to prevent claustrophobia induced by MR imaging. AJR 2001; 176:865.</li>
</ol>
<p class="extra_spacing_top">Courtesy of authors with additional data from Gan TJ. Pharmacokinetic and pharmacodynamic characteristics of medications used for moderate sedation. Clin Pharmacokinet 2006; 45:855 and Lexicomp Online. Copyright © 1978-2024 Lexicomp, Inc. All Rights Reserved.</p></div><div id="graphicVersion">Graphic 71754 Version 19.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
